{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"GEN602","nct_id":"NCT03775525","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=gen602-nct03775525. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"GEN602","arms":[{"description":"GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.","label":"Experimental: monotherapy","type":"EXPERIMENTAL"},{"description":"GZ17-6.02 given orally twice daily x 21 day schedule in combination with Capecitabine 825 mg/m2 orally twice daily for 14 days x 21 day schedule.","label":"Experimental: Combination with Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer","type":"EXPERIMENTAL"},{"description":"GZ17-6.02 given orally twice daily x 21 day schedule in combination with Capecitabine 850 mg/m2 orally twice daily for 14 days x 21 day schedule.","label":"Experimental: Combination with Capecitabine in Metastatic Colorectal Cancer","type":"EXPERIMENTAL"}],"collaborators":["Translational Drug Development"],"completion_date":{"date":"2023-12","type":"ESTIMATED"},"conditions":["Advanced Cancer","Gastric Cancer","Breast Cancer","Pancreatic Cancer","Prostate Cancer Metastatic","Colo-rectal Cancer","Solid Tumor","Solid Carcinoma","Solid Carcinoma of Stomach","Cancer of Stomach","Lymphoma","Sarcoma","Cutaneous T Cell Lymphoma","Head and Neck Squamous Cell Carcinoma","Basal Cell Carcinoma","Cutaneous T-cell Lymphoma","Cutaneous Squamous Cell Carcinoma"],"enrollment":{"count":127,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"GZ17-6.02","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"}],"last_update":"2022-12-23","lead_sponsor":"Genzada Pharmaceuticals USA, Inc.","official_title":"A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma","overall_status":"UNKNOWN","phases":["PHASE1"],"primary_completion_date":{"date":"2023-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"maximum tolerated dose (MTD)","timeFrame":"18 months"},{"measure":"Recommended dose of GZ17-6.02 for future phase II clinical studies","timeFrame":"18 months"},{"measure":"Dose-limiting toxicity","timeFrame":"18 months"}],"references":[{"citation":"Booth L, Roberts JL, Spasojevic I, Baker KC, Poklepovic A, West C, Kirkwood JM, Dent P. GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17;15:328-344. doi: 10.18632/oncotarget.28586.","pmid":"38758815","type":"DERIVED"},{"citation":"Booth L, West C, Von Hoff D, Dent P. Mechanisms of GZ17-6.02 resistance. Anticancer Drugs. 2022 Jun 1;33(5):415-423. doi: 10.1097/CAD.0000000000001203.","pmid":"35276694","type":"DERIVED"}],"start_date":{"date":"2019-03-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03775525"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/gen602-nct03775525"}